Antibodies derived from patient tumors augment response to immune checkpoint blockade in cancer 3582

Abstract Description Background B-cells and Tertiary Lymphoid Structures (TLS) are associated with response to Immune Checkpoint Blockade (ICB) but their functional role remains unexplored. Here, we evaluate the therapeutic efficacy of tumor-derived antibodies in combination with ICB-based regimen. Methods and Results Tumors from ICB-treated melanoma patients were analyzed. Major pathologic response (MPR) was used to evaluate response (R – responder; NR – non-responder). TLS were analyzed on GeoMx which revealed distinct transcriptional states by response (r = 0.88, p < 0.0001). R-TLS were enriched for CD8+ T-cells, NK cells, memory B-cells and NK-cell cytotoxicity pathways (p < 0.05). BCR sequencing of patient specimen (R = 9, NR = 3) yielded 546 unique antibodies. R-BCR had enhanced somatic hypermutation (p = 7.2e-9) and isotype switching (50.1% R vs 32.6% NR). Flow cytometry identified 73 antibodies that bound A375 human melanoma cells. Antibody dependent cell cytotoxicity (ADCC) assay identified 10 melanoma-binding antibodies that induced significant cell death of A375 and BP murine melanoma cells. In vivo experiments identified 4 ADCC+ antibodies that homed to BP tumors with systemic delivery. One clone, RAPC5-7-156, synergized with αPD-L1 to reduce BP tumor growth compared to isotype (p = 0.0003) and α-PD-L1 only (p = 0.005). Conclusion Tumor-derived antibodies are capable of augmenting response to ICB. This presents new opportunities for tumor target discovery and for improving clinical outcomes to ICB. Funding Sources This work is supported by the Mark Foundation for Cancer Research (#AWD00005025 to J. Wargo, K. McBride, T. Cascone, and T. Bruno) and the Adelson Medical Research Foundation (#04-7023433 to J. Wargo). Topic Categories Tumor Immunology: Cellular Responses and Tumor Microevironment (TIME)

Authors

Institutions

Publication Details

Journal
The Journal of Immunology
Published
2025-11-01
DOI
https://doi.org/10.1093/jimmun/vkaf283.1367
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Antibodies derived from patient tumors augment response to immune checkpoint blockade in cancer 3582

Diana D. Shamsutdinova, Y David Seo, Joshua B. Plummer, Florentia Dimitriou et al.
The Journal of Immunology
Cancer Immunotherapy and Biomarkers
article

Antibodies derived from patient tumors augment response to immune checkpoint blockade in cancer 3582

Diana D. Shamsutdinova, Y David Seo, Joshua B. Plummer, Florentia Dimitriou, Rebecca Soto, Davis R. Ingram, Nadim J. Ajami, Matthew Lastrapes, Michael G. White, Khalida Wani, Jennifer Ann Wargo, Melissa Simper, Rossana Lazcano, Somnath Paul, Tullia C. Bruno, Brenda Melendez, James P. Allison, Alexander J. Lazar, Golnaz Morad, Manoj Chelvanambi, Tina Cascone, Russell Gardner Witt, Sarah B. Johnson, Monika A. Zelazowska, Padmanee Sharma, Wolf H. Fridman, Laurence P. Diggs, Beth A. Helmink, Emily Z. Keung, Elise F. Nassif, Christina Lynn Roland, Fabiana J. Veguilla, Bin Liu, Bharat Singh, Kevin M. McBride
article en

Abstract

Abstract Description Background B-cells and Tertiary Lymphoid Structures (TLS) are associated with response to Immune Checkpoint Blockade (ICB) but their functional role remains unexplored. Here, we evaluate the therapeutic efficacy of tumor-derived antibodies in combination with ICB-based regimen. Methods and Results Tumors from ICB-treated melanoma patients were analyzed. Major pathologic response (MPR) was used to evaluate response (R – responder; NR – non-responder). TLS were analyzed on GeoMx which revealed distinct transcriptional states by response (r = 0.88, p < 0.0001). R-TLS were enriched for CD8+ T-cells, NK cells, memory B-cells and NK-cell cytotoxicity pathways (p < 0.05). BCR sequencing of patient specimen (R = 9, NR = 3) yielded 546 unique antibodies. R-BCR had enhanced somatic hypermutation (p = 7.2e-9) and isotype switching (50.1% R vs 32.6% NR). Flow cytometry identified 73 antibodies that bound A375 human melanoma cells. Antibody dependent cell cytotoxicity (ADCC) assay identified 10 melanoma-binding antibodies that induced significant cell death of A375 and BP murine melanoma cells. In vivo experiments identified 4 ADCC+ antibodies that homed to BP tumors with systemic delivery. One clone, RAPC5-7-156, synergized with αPD-L1 to reduce BP tumor growth compared to isotype (p = 0.0003) and α-PD-L1 only (p = 0.005). Conclusion Tumor-derived antibodies are capable of augmenting response to ICB. This presents new opportunities for tumor target discovery and for improving clinical outcomes to ICB. Funding Sources This work is supported by the Mark Foundation for Cancer Research (#AWD00005025 to J. Wargo, K. McBride, T. Cascone, and T. Bruno) and the Adelson Medical Research Foundation (#04-7023433 to J. Wargo). Topic Categories Tumor Immunology: Cellular Responses and Tumor Microevironment (TIME)

The Journal of ImmunologyVol. 214(Supplement_1)
The University of Texas MD Anderson Cancer Center (US), University of Pittsburgh (US)
National Research Foundation, National Research Foundation of Korea, Ministry of Science and ICT, South Korea
Openalex Percentile: Top 52%
Cancer Immunotherapy and Biomarkers
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.